Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 5/12/2019
SIETES contiene 92850 citas

 1 a 20 de 33 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Marciniak TA, Cherepanov V, Golukhova I, Hyun Kim M, Serebruany V. Drug discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern Med 2016;176:11 de enero. [Ref.ID 99961]
2.Enlace a cita original Cita con resumen
Montalescot G, Sabatine MS. Oral dual antiplatelet therapy: what have we learnt from recent trials?. Eur Heart J 2015:6 de agosto. [Ref.ID 99343]
3. Cita con resumen
Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F, Barthélémy O, Collet J-P, Jacq L, Bernasconi F, Montalescot G, for the ACTION Study Group. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ 2014;349:g6269. [Ref.ID 98292]
4.Tiene citas relacionadas Cita con resumen
Gagne JJ, Bykov K, Choudhry NK, Toomey TJ, Connolly JG, Avorn J. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ 2013;347:11. [Ref.ID 96346]
5.Tiene citas relacionadas Cita con resumen
Hirschl MM. Smoking status and the effects of antiplatelet drugs. BMJ 2013;347:10. [Ref.ID 96345]
6. Cita con resumen
Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA 2012;307:2495-6. [Ref.ID 93316]
7.Enlace a cita original
Passacquale G, Ferro A. Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events. BMJ 2011;342:1415-20. [Ref.ID 90956]
8.Tiene citas relacionadas Cita con resumen
Fuster V, Sweeny JM. Clopidogrel and the reduced-function CYP2C19 genetic variant. JAMA 2010;304:1839-8140. [Ref.ID 89226]
9. Cita con resumen
Schömig A. Ticagrelor-Is there need for a new player in the antiplatelet-therapy field?. N Engl J Med 2009;361:1108-11. [Ref.ID 86475]
10.Tiene citas relacionadas Cita con resumen
Schneider-Lindner V, Filion KB, Brophy JM. Adverse outcomes associated with use of proton pump inhibitors and clopidogrel. JAMA 2009;302:29-30. [Ref.ID 86151]
11.Tiene citas relacionadas Cita con resumen
Burrill PD. Clopidogrel. Increasing concordance. BMJ 2009;338:1226. [Ref.ID 85957]
12.Tiene citas relacionadas Cita con resumen
Chua D, Ignaszewski A. Clopidogrel in acute coronary syndromes. BMJ 2009;338:998-1002. [Ref.ID 85705]
13. Cita con resumen
Anónimo. Antiplatelet therapy for patients with stents. Med Lett Drugs Ther 2008;50:61-3. [Ref.ID 83808]
15.Tiene citas relacionadas
Connolly S, Yusuf S, on behalf of the ACTIVE Investigators. Prevention of vascular events in atrial fibrillation. Authors' reply. Lancet 2007;369:106. [Ref.ID 78852]
16.Tiene citas relacionadas
King A, Bhala N. Prevention of vascular events in atrial fibrillation. Lancet 2007;369:106. [Ref.ID 78851]
17.Tiene citas relacionadas
Cheng Hy. Prevention of vascular events in atrial fibrillation. Lancet 2007;369:105-6. [Ref.ID 78850]
18.Tiene citas relacionadas Cita con resumen
Verheugt FWA. Good old warfarin for stroke prevention in atrial fibrillation. Lancet 2006;367:1877-8. [Ref.ID 77184]
19. Cita con resumen
Anónimo. Clopidogrel (Plavix) revisited. Med Lett Drugs Ther 2006;48:29-31. [Ref.ID 76844]
Tricoci P, Roe MT, Mulgund J, Newby LK, Smith Jr SC, Pollack Jr CV, Fintel DJ, Cannon CP, Bhatt DL, Gibler B, Ohman EM, Peterson ED, Harrington RA. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 2006;166:806-11. [Ref.ID 76709]
Seleccionar todas
 1 a 20 de 33 siguiente >>